GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (LTS:0ND5) » Definitions » Debt-to-Revenue

H. Lundbeck AS (LTS:0ND5) Debt-to-Revenue : 0.20 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

H. Lundbeck AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr85 Mil. H. Lundbeck AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr4,078 Mil. H. Lundbeck AS's annualized Revenue for the quarter that ended in Mar. 2024 was kr21,152 Mil. H. Lundbeck AS's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.20.


H. Lundbeck AS Debt-to-Revenue Historical Data

The historical data trend for H. Lundbeck AS's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

H. Lundbeck AS Debt-to-Revenue Chart

H. Lundbeck AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.45 0.33 0.31 0.21

H. Lundbeck AS Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.25 0.21 0.21 0.20

Competitive Comparison of H. Lundbeck AS's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


H. Lundbeck AS's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's Debt-to-Revenue falls into.



H. Lundbeck AS Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

H. Lundbeck AS's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(86 + 4065) / 19912
=0.21

H. Lundbeck AS's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(85 + 4078) / 21152
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


H. Lundbeck AS Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


H. Lundbeck AS (LTS:0ND5) Business Description

Address
Ottiliavej 9, Valby, DNK, 2500
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS (LTS:0ND5) Headlines

No Headlines